From: A randomized controlled trial of iliopsoas plane block vs. femoral nerve block for hip arthroplasty
IPB (n = 45) | FNB (n = 45) | P value | |
---|---|---|---|
Primary Outcome | |||
Pain Score during flexion of hip at 4 h | 1 (0–2[0–4]) | 1 (1–2[0–5]) | 0.896 |
Secondary Outcome | |||
Pain score at rest in PACU | 0 (0–1[0–4]) | 0 (0–0.5[0–4]) | 0.491 |
Pain score at rest at 2 h | 0 (0–1[0–4]) | 0 (0–1[0–2]) | 0.988 |
Pain score at rest at 4 h | 0 (0–1[0–3]) | 0 (0–1[0–3]) | 0.849 |
Pain score at rest at 6 h | 0 (0–0.5[0–3]) | 0 (0–1[0–3]) | 0.554 |
Pain score at rest at 24 h | 0 (0–0 [0–3]) | 0 (0–0[0–2]) | 0.542 |
Pain score at rest at 48 h | 0 (0–0 [0–4]) | 0 (0–0[0–1]) | 0.887 |
Pain Score during flexion of hip in PACU | 1 (0–2[0–5]) | 1 (0–1[0–6]) | 0.862 |
Pain Score during flexion of hip at 2 h | 1 (0–2[0–5]) | 1 (1–2[0–4]) | 0.713 |
Pain Score during flexion of hip at 6 h | 1 (0–2[0–4]) | 1 (1–1.5[0–4]) | 0.469 |
Pain Score during flexion of hip at 24 h | 1 (1–2[0–4]) | 1 (1–1[0–2]) | 0.080 |
Pain Score during flexion of hip at 48 h | 1 (0–2[0–5]) | 1 (1–1 [0–3]) | 0.418 |
Quadriceps strength in PACU | 4 (3–4[2-5]) | 1 (1–2[1,2]) | 0.000 |
Quadriceps strength at 2 h | 4 (4–5[3-5]) | 1 (1–2[1,2,3]) | 0.000 |
Quadriceps strength at 4 h | 5 (4–5[3-5]) | 2 (1–2.5[1-4]) | 0.000 |
Quadriceps strength at 6 h | 5 (5–5[4,5]) | 3 (2–3[2-5]) | 0.000 |
Quadriceps strength at 24 h | 5 (5–5[4,5]) | 4 (3–5[3,4,5]) | 0.000 |
Quadriceps strength at 48 h | 5 (5–5[4,5]) | 5 (5–5[3,4,5]) | 0.089 |
Total opioids consumption; mg OME | 30 (0–45 [0–60]) | 30 (0–45[0–90]) | 0.772 |
First time out of bed; h | 8 (6.5–11[4-14]) | 24(20–28[18–33]) | 0.000 |
Patient satisfaction | 9 (8–10[5-10]) | 9 (8–10[6-10]) | 0.20 |
Dizziness | 2 (4%) | 3 (7%) | 1.000 |
Nausea and vomiting | 5 (11%) | 5 (11%) | 1.000 |
Nerve injury | 0 (0%) | 0 (0%) | - |
Vascular injury | 0 (0%) | 0 (0%) | - |
Infection | 0 (0%) | 0 (0%) | - |
Delirium | 0 (0%) | 1 (2%) | 1.000 |
Deep venous thrombosis | 3 (7%) | 2 (4%) | 1.000 |
Falls in-hospital | 0 (0%) | 1 (2%) | 1.000 |